Royalty Pharma (RPRX) Net Cash Flow Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 301.06% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - | -120.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120.35% |
| Dec 31, 2025 | -1,423.10% |
| Sep 30, 2025 | 137.69% |
| Jun 30, 2025 | -149.46% |
| Mar 31, 2025 | -56.64% |
| Dec 31, 2024 | 95.42% |
| Sep 30, 2024 | 34.13% |
| Jun 30, 2024 | 366.92% |
| Mar 31, 2024 | 38.14% |
| Dec 31, 2023 | -163.89% |
| Sep 30, 2023 | -10.77% |
| Jun 30, 2023 | -37.64% |
| Mar 31, 2023 | 5.78% |
| Dec 31, 2022 | 376.84% |
| Sep 30, 2022 | -269.53% |
| Jun 30, 2022 | -26.98% |
| Mar 31, 2022 | 183.53% |
| Dec 31, 2021 | 52.26% |
| Sep 30, 2021 | 185.66% |
| Jun 30, 2021 | -76.23% |